NOVEL PSMA-SPECIFIC BINDING PROTEINS
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F21%3A00557143" target="_blank" >RIV/86652036:_____/21:00557143 - isvavai.cz</a>
Result on the web
<a href="https://worldwide.espacenet.com/patent/search/family/053540662/publication/EP3319641B1?q=pn%3DEP3319641B1" target="_blank" >https://worldwide.espacenet.com/patent/search/family/053540662/publication/EP3319641B1?q=pn%3DEP3319641B1</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
NOVEL PSMA-SPECIFIC BINDING PROTEINS
Original language description
The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KDof 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention. In addition, the present invention relates to a pharmaceutical or diagnostic composition, to the PSMA-specific binding protein of the invention, the nucleic acid molecule of the invention, the vector of the invention, the host cell of the invention or the PSMA-specific binding protein produced by the method of the invention, for use in therapy and/or diagnosis, and in particular for use in the therapy and/or diagnosis of tumors, Crohn's disease and/or neurological diseases.
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
EP 3319641
Publisher
EPO_1 -
Publisher name
European Patent Office
Place of publication
Munich, The Hague, Berlin, Vienna, Brussels
Publication country
—
Date of acceptance
Apr 14, 2021
Owner name
Technische Universitaet Muenchen, Biotechnologický ústav AV ČR, v. v. i.
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence